Event context and recent share performance
Novanta (NOVT) has attracted investor attention after recent share price moves, with the stock closing at US$138.18. The company operates in precision medicine, manufacturing, robotics, automation, and advanced surgery technology.
See our latest analysis for Novanta.
The recent pullback, with a 1-day share price return of a 1.81% decline to US$138.18, sits against a stronger backdrop, including a 90-day share price return of 20.91% and a 5-year total shareholder return of 10.25%. This suggests momentum has recently been building despite more muted long term gains.
If Novanta’s recent move has you looking beyond a single name, this could be a good moment to scan for other opportunities in robotics and automation through our 31 robotics and automation stocks.
With Novanta trading at US$138.18, annual revenue of US$980.6m and net income of US$53.829m, plus a 1 year total return that is slightly negative, you might ask: is there real value here, or is the market already pricing in future growth?
Most Popular Narrative: 10.3% Undervalued
At a last close of $138.18 versus a narrative fair value of $154, the prevailing view sees upside potential, built on specific growth and margin assumptions.
The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady.
Revenue Growth: Held steady at about 6.83%, indicating no meaningful change in long term growth assumptions.
Want to understand why this narrative still backs a higher value even after the recent run up? The heart of it is a blend of mid single digit revenue growth, expanding profitability and a future earnings multiple that leans on confidence in Novanta’s robotics and medical exposure. Curious which assumptions really carry that $154 figure? The full narrative lays out the math behind that view.
Result: Fair Value of $154 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story could be challenged if trade disruptions hit the US$35 million of export sales to China, or if flat to slightly negative organic growth persists.
Find out about the key risks to this Novanta narrative.
Another angle on valuation
Those fair value narratives paint Novanta as 10.3% undervalued, but the current P/E of 91.6x tells a very different story. It is far above the Electronic industry at 27.2x, peers at 61.2x, and even the 39.7x fair ratio our model suggests the market could move toward. Is that a premium you are comfortable paying?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals so far, right? If this has you weighing both the upside and the risks, take a moment to look through the numbers yourself and stress test your view against the 1 key reward and 1 important warning sign.
Looking for more investment ideas?
If this story has sharpened your thinking, do not stop here. Use the screener to quickly line up other stocks that match your standards.
- Target value by checking companies our screener tags as 49 high quality undervalued stocks based on their fundamentals.
- Prioritise resilience with a curated set of 75 resilient stocks with low risk scores that score well on stability and risk checks.
- Hunt for potential future leaders hiding in plain sight with our screener containing 24 high quality undiscovered gems that many investors may be overlooking.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com